Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
Adamson, Karen Reid, Hazel Barnes, Dennis Sivappriyan, Siva Bickerton, Alex Gallen, Ian W Field, Benjamin C T Idris, Iskandar
Adamson, Karen
Reid, Hazel
Barnes, Dennis
Sivappriyan, Siva
Bickerton, Alex
Gallen, Ian W
Field, Benjamin C T
Idris, Iskandar
Abstract
The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure. The analysis, in this research letter, shows that decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP-1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide, potentially suggesting differing potencies between GLP-1RAs. Dedicated studies with head-to-head comparisons are needed to confirm these findings.
MIDER Authors
Citations
Altmetric:
Date
2022-04-07
Type
Article
Subject
Diabetes
Collections
Citation
Crabtree, T. S. J., Adamson, K., Reid, H., Barnes, D., Sivappriyan, S., Bickerton, A., Gallen, I. W., Field, B. C. T., Idris, I., Ryder, R. E. J., & all ABCD semaglutide audit contributors (2022). Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. Diabetes, obesity & metabolism, 24(7), 1398–1401. https://doi.org/10.1111/dom.14701
Journal / Source Title
Diabetes, Obesity and Metabolism
DOI
10.1111/dom.14701
PMID
35322528
Publisher
Wiley